RGNT (Regentis Biomaterials) Research & Development: $0.33 Mil (TTM As of Dec. 2025)


RGNT Regentis Biomaterials Ltd RGNT
14 GF Score
Price $4.15
! 2 Warning Signs
View Full Analysis

What is Regentis Biomaterials Research & Development?

Regentis Biomaterials RGNT -1.19% 14 Research & Development is $0.33 Mil as of Dec. 2025. GuruFocus rates RGNT with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Regentis Biomaterials's Research & Development for the six months ended in Dec. 2025 was $0.15 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $0.33 Mil.

Regentis Biomaterials  (AMEX:RGNT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Regentis Biomaterials Research & Development Related Terms

Regentis Biomaterials Research & Development Historical Data

* Premium members only.

The historical data trend for Regentis Biomaterials's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regentis Biomaterials Research & Development Chart

Regentis Biomaterials Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.34 0.97 0.81 -1.64 0.33

Regentis Biomaterials Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.39 -2.17 0.53 0.18 0.15
RGNT
14GF Score
Regentis Biomaterials Ltd RGNT
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regentis Biomaterials Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.33 Mil mean?
Regentis Biomaterials (RGNT) has a Research & Development of $0.33 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Regentis Biomaterials and its competitors.
Is Regentis Biomaterials' Research & Development too high?
Regentis Biomaterials' current Research & Development is $0.33 Mil. Overall, Regentis Biomaterials has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Regentis Biomaterials' Research & Development compare to MHUAF and LUCY?
Regentis Biomaterials' Research & Development of $0.33 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Regentis Biomaterials and its competitors. Regentis Biomaterials's current Research & Development is $0.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regentis Biomaterials stock overvalued right now?
Regentis Biomaterials (RGNT) has a current Research & Development of $0.33 Mil. The current Research & Development is $0.33 Mil. Regentis Biomaterials' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Regentis Biomaterials (RGNT), the current Research & Development is $0.33 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regentis Biomaterials Business Description

Address 60, Medinat Hyahudim, Entrance C, Herzlia Pituach, ISR, 4676652
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
14GF Score

Get the complete analysis for RGNT

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.15
Price